Lipoprotein(a) and CKD
Clinical Journal of the American Society of Nephrology · 2026
DOI: 10.2215/cjn.0000000968 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Journal of the American Society of Nephrology, 2026. Verfasst von Enkhmaa Byambaa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, School of Medicine, University of California-Davis, Davis, California. Hauptthemen laut MEDLINE: Lipoprotein(a), Cardiovascular Diseases, Renal Insufficiency, Chronic, Hypolipidemic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Lipoprotein(a) (Lp[a]) was discovered more than six decades ago. Since then, it has evolved from a subject of curious experiments performed by a few scientists to an extensively explored therapeutic target for prevention and management of cardiovascular disease (CVD). This has prompted an intense search for therapies and agents with potent Lp(a)-specific lowering effects on the horizon. Some of these agents are already in clinical trials to clarify whether lowering high Lp(a) levels would result in reductions in CVD events. The road to this point has been filled with many challenges, where landmark genetic discoveries opened new avenues and set the stage for interventions. Although there is no doubt that genetics play a key role in determining Lp(a) level, accumulating evidence also supports a role for some clinical conditions in influencing Lp(a) levels. CKD is a prevalent condition associated with elevated Lp(a) levels. Most available data show that elevated Lp(a) levels predict CVD risk in patients with CKD. Given the growing evidence for a relationship between Lp(a), CVD, and CKD as well as ongoing cardiovascular outcomes trials of Lp(a)-specific agents, we provide an overview of recent evidence on this topic. We focus on recent studies in patients with CKD on treatment modalities affecting Lp(a) level as well as on existing gaps in knowledge and future research directions related to clinical care and CVD risk reduction in patients with CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, School of Medicine, University of California-Davis, Davis, California.
ORCID-Profile: Enkhmaa Byambaa, Lars Berglund
Förderung
- NIDDK NIH HHS
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Byambaa, E., Roshanravan, B., & Berglund, L. (2026). Lipoprotein(a) and CKD. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.0000000968
Vancouver
Byambaa E, Roshanravan B, Berglund L. Lipoprotein(a) and CKD. Clinical Journal of the American Society of Nephrology. 2026. doi:10.2215/cjn.0000000968
BibTeX
@article{Byambaa2026,
author = {Byambaa, Enkhmaa and Roshanravan, Baback and Berglund, Lars},
title = {Lipoprotein(a) and CKD},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2026},
doi = {10.2215/cjn.0000000968}
}
EUVIMED